insights_auto
Outlook: 48.6% bullish·0.0% bearish
Go to analysischevron_right
GILD:NASDAQ
गिलियड साइन्सेस
US$ १५६.१९
arrow_downward
-०.७५%(-१.१८) 1D
US$ १५६.८४
arrow_upward
+०.४२% (+०.६५)bedtimeAfter hours
Closed: अक्टोबर १६, १६:००:०२ GMT-४ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GILD...
Open
US$ १५७.३२
High
US$ १५७.५८
Low
US$ १५५.६२
Mkt. cap
१.९४ खरब
Avg. vol.
५७.८६ लाख
Volume
७७.७२ लाख
Dividend
२.१०%
Quarterly dividend
US$ ०.८२
Ex-dividend date
२०२६ सेप्टेम्बर १५
52-wk high
US$ १६०.५१
52-wk low
US$ ११४.०२
EPS
-US$ २.६६
Beta
०.३२
Shares outstanding
१.२४ अरब
No. of employees
१७ हजार
Open
US$ १५७.३२
High
US$ १५७.५८
Low
US$ १५५.६२
Mkt. cap
१.९४ खरब
Avg. vol.
५७.८६ लाख
Volume
७७.७२ लाख
Dividend
२.१०%
Quarterly dividend
US$ ०.८२
Ex-dividend date
२०२६ सेप्टेम्बर १५
52-wk high
US$ १६०.५१
52-wk low
US$ ११४.०२
EPS
-US$ २.६६
Beta
०.३२
Shares outstanding
१.२४ अरब
No. of employees
१७ हजार
News stories
From web sources and news partners
Simply Wall Street
·
१ घण्टा पहिले
Did Cancer Drug Partnership Just Shift Gilead's (GILD) Investment Narrative?
Investing.com Nigeria
·
३ घण्टा पहिले
Gilead chairman & CEO O’Day sells $2.2m in stock
MarketBeat
·
६ घण्टा पहिले
Gilead Sciences, Inc. $GILD Stock Sold by New England Research & Management Inc.
Investing.com Nigeria
·
१४ घण्टा पहिले
Gilead chief comm & corp aff officer sells $468,660 in GILD shares
Profile
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
About गिलियड साइन्सेस
CEODaniel O'Day
Employees१७ हजार
Founded१९८७ जुन २२
HeadquartersFoster City, क्यालिफोर्निया, संयुक्त राज्य अमेरिका
Sector-
Websitegilead.com